VTEU COVID-19 Trials

The experimental vaccine, mRNA-1273, was co-developed by researchers at the NIAID, part of the National Institutes of Health, and biotech company Moderna, Inc. of Cambridge, Massachusetts.

The study, called the Adaptive COVID-19 Treatment Trial 3 (ACTT 3), is anticipated to enroll more than 1,000 hospitalized adults with COVID-19 at as many as 100 sites in the U.S. and abroad. National Institute of Allergy and Infectious Diseases (NIAID) is sponsoring the trial.

An investigational vaccine designed to protect against COVID-19 resulted in production of both binding and neutralizing antibodies in healthy adult volunteers, according to interim results of an ongoing phase 1 trial published in the NEJM. The Phase 1 trial was led and supported by IDCRC sites.

The NIAID-sponsored, Infectious Diseases Clinical Research Consortium (IDCRC) and the nation’s Vaccine Trials and Evaluation Units (VTEUs) enrolled a quarter of all patients in this international study.

The IDCRC works through a flexible, sustaining structure to advance new countermeasures and approaches to product development, implement efficient clinical study/trial designs, and support exceptional career development and mentoring of future leaders in infectious diseases clinical research. The consortium's collective experience and access to diverse populations give it the ability to evaluate new vaccines and therapies for infectious diseases.

Logos and headshots of the leadership group
Logos and headshots for each VTEU

NIAID Division of Microbiology and Infectious Diseases (DMID)